Immuneering Corporation (NASDAQ:IMRX) Stock Has Average Price Target of $15.67

Immuneering Corporation (NASDAQ:IMRX) has received a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $15.67.

A number of brokerages have recently commented on IMRX. UBS Group set a $14.00 target price on shares of Immuneering in a research note on Thursday, August 6th. Mizuho set a $11.00 price target on shares of Immuneering in a research report on Thursday, October 29th. HC Wainwright reiterated a “buy” rating on shares of Immuneering in a report on Friday, October 30th. Chardan Capital raised Immuneering to a “strong-buy” rating in a research report on Monday, August 3rd. Finally, Needham & Company LLC raised their price objective on Immuneering from $11.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, July 20th.

Institutional Investors Weigh In On Immuneering

A number of large investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC purchased a new position in Immuneering in the 2nd quarter worth approximately $34,000. Levin Capital Strategies L.P. acquired a new stake in Immuneering in the first quarter valued at approximately $53,000. VestGen Advisors LLC raised its stake in shares of Immuneering by 100.0% during the third quarter. VestGen Advisors LLC now owns 20,002 shares of the company’s stock valued at $82,000 after purchasing an additional 10,002 shares during the period. Focus Financial Network Inc. purchased a new stake in shares of Immuneering during the second quarter valued at approximately $62,000. Finally, Principle Wealth Partners LLC purchased a new stake in shares of Immuneering during the third quarter valued at approximately $51,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

Immuneering Stock Performance

NASDAQ IMRX opened at $3.37 on Tuesday. Immuneering has a one year low of $3.35 and a one year high of $8.48. The company’s 50 day moving average price is $4.15 and its 200 day moving average price is $4.78. The firm has a market capitalization of $218.24 million, a price-to-earnings ratio of -3.27 and a beta of 0.49.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings results on Thursday, October 29th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.06). Sell-side analysts forecast that Immuneering will post -1.19 EPS for the current fiscal year.

Immuneering Company Profile

Immuneering Corporation is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company uses computational biology and drug-discovery technologies to identify therapeutic opportunities in complex biological pathways, with a particular emphasis on the RAS–RAF–MEK–ERK signaling pathway, which is frequently altered in cancer.

Immuneering’s lead product candidate, IMM-1-104, is an orally administered pan-RAF inhibitor designed to provide deep and durable suppression of the MAP kinase pathway while potentially limiting treatment resistance.